Personalized anti-rejection therapy with alemtuzumab for kidney transplant recipients

Dennis A Hesselink^{1

2}, Daphne M Hullegie-Peelen^{1

2}, Lukas K van Vugt^{1

2}

Affiliations

¹ Erasmus MC Transplant Institute, Rotterdam, The Netherlands.
² Department of Internal Medicine, Division of Nephrology & Transplantation, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Editorial

Dennis A Hesselink et al. Pharmacogenomics. 2022 Jul.

. 2022 Jul;23(10):567-570.

doi: 10.2217/pgs-2022-0071. Epub 2022 Jun 28.

Dennis A Hesselink^{1

2}, Daphne M Hullegie-Peelen^{1

2}, Lukas K van Vugt^{1

2}

¹ Erasmus MC Transplant Institute, Rotterdam, The Netherlands.
² Department of Internal Medicine, Division of Nephrology & Transplantation, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

No abstract available

Keywords: acute rejection; alemtuzumab; immunosuppression; kidney; pharmacokinetics; transplantation.

Publication types